Alumis and ACELYRIN to Merge, Forming Biopharma Leader in Immune-mediated Therapies

Alumis Inc. and ACELYRIN, two biopharmaceutical companies, have announced their merger in an all-stock transaction, forming a late-stage clinical biopharma entity focused on therapies for immune-mediated diseases. Alumis stockholders will own 55% of the new company, retaining the Alumis name and executive team, while ACELYRIN stockholders will own 45%. The combined company's portfolio will include several advanced product candidates, such as Alumis's ESK-001 and A-005, as well as ACELYRIN's lonigutamab, with expectations of significant data readouts from ongoing trials by 2026. The merger aims to optimize resources and accelerate the development of transformative medicines, backed by a robust financial position with a pro forma cash of $737 million. This transaction is subject to requisite approvals and expected to close in the second quarter of 2025.